In elderly men given influenza vaccine, no toxicity was observed with thymosin alpha‑1 or placebo.
In plain wordsIn elderly men given influenza vaccine, no toxicity was seen with thymosin alpha‑1 or with placebo.
- Peptide
- Thymosin alpha-1
- Outcome
- No significant changeToxicity
- Study
n = 90
- Comparator
- Placebo
- Outcome group
- Adverse events · Whole body
- Studied dose
- 900 micrograms/m2 twice weekly · subcutaneous · eight dosesAs given in this study (human).
Source sentences
No toxicity was observed in either group.
2 context sentences(design, population, supporting numbers)
To test whether administration of thymosin alpha 1 would result in greater antibody production, we administered it (900 micrograms/m2 subcutaneously twice weekly for eight doses) in conjunction with the 1986 trivalent influenza vaccine.
Ninety men (65-99 years old, mean age 77.3 years) were randomized double-blind to receive thymosin alpha 1 or placebo by the same schedule; the sera from 85 of these men were acceptable for analysis.